Archive | News: Pharma RSS feed for this section

Ophthalmic Pharmaceuticals Company Paragon BioTeck Receives CE Mark Approval on Comfortear Lacrisolve Absorbable Punctum Plug

PORTLAND, Ore. /eNewsChannels/ — NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear Lacrisolve Absorbable Punctum Plug. CE mark approval is recognized and associated with safety and performance in multiple countries.

TOPICS: Business, News: Pharma, Newsdesk, State: Oregon
 
» Continue Reading

American Academy of Ophthalmology Annual Meeting 2014 to include exhibit from Paragon BioTeck, Inc.

PORTLAND, Ore. /eNewsChannels/ — NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago on October 18-21, 2014.

TOPICS: Medical, News: Pharma, Newsdesk, State: Oregon
 
» Continue Reading

SilkTears, LLC cites advances in protein-based excipient technology may allow for the development of artificial tear products

PLYMOUTH, Minn. /eNewsChannels/ — NEWS: SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.

TOPICS: Medical, News: Pharma, Newsdesk, State: Minnesota
 
» Continue Reading

Lakewood College announces Pharmacy Technician Program with debt-free payment plan

CLEVELAND, Ohio /eNewsChannels/ — NEWS: Ohio’s Lakewood College today announced a new payment plan option that will allow students to graduate from the Pharmacy Technician Certificate Program without going thousands of dollars into debt. Lakewood College is committed to helping students achieve their goals affordably.

TOPICS: Medical, News: Pharma, Newsdesk, State: Ohio
 
» Continue Reading

Paragon BioTeck’s FDA Approved Phenylephrine Hydrochloride Ophthalmic Solution Readily Available through Bausch + Lomb

PORTLAND, Ore. /eNewsChannels/ — NEWS: Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb.

TOPICS: Medical, News: Pharma, Newsdesk, State: Oregon
 
» Continue Reading

Jury Awards $9B to a New York man who developed bladder cancer after taking Actos

NEW YORK CITY, N.Y. /eNewsChannels/ — NEWS: Actos manufacturer Takeda and its partner Eli Lilly were hit this week with a $9 Billion verdict over the safety of their popular diabetes drug. After a two month trial, the jury found that Weitz and Luxenberg client Terrence Allen’s use of Actos caused bladder cancer and the drug manufacturer and marketer failed to warn of this life-threatening risk.

TOPICS: Legal and Law, News: Pharma, Newsdesk, State: New York
 
» Continue Reading

Paragon BioTeck, Inc. receives FDA Approval for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent

PORTLAND, Ore. /eNewsChannels/ — NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

TOPICS: Business, News: Pharma, Newsdesk, State: Oregon
 
» Continue Reading

SignatureCLL SignatuRx Test for Patients with Chronic Lymphocytic Leukemia Shown to Reduce Early Cancer Deaths

HUNTINGTON BEACH, Calif. /eNewsChannels/ — NEWS: SignatureCLL today announced that the first laboratory test ever shown in a clinical trial to improve one year survival rates in cancer is now available to patients with chronic lymphocytic leukemia (CLL). The U.S. cancer physician who invented the test and the British scientist who used it to make discoveries in leukemia will offer the test under the trade name SignatuRx through their own, newly-formed laboratory company.

TOPICS: Business, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Paragon BioTeck to launch new line of eyecare products at the Annual American Academy of Ophthalmology meeting

PORTLAND, Ore. /eNewsChannels/ — NEWS: Biopharmaceutical company Paragon BioTeck, Inc. today announced that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.

TOPICS: Business, Medical, News: Pharma, Newsdesk, State: Oregon
 
» Continue Reading

Dr. Rick Lentini of Nutronics Labs explains what makes a reputable deer antler spray company

CHICAGO, Ill. /eNewsChannels/ — NEWS: Nutronics Labs, a Natural supplement company, today released a statement encouraging deer antler spray consumers to do thorough product research before buying health supplements online. Nutronics Labs is the leading manufacturer of deer antler spray and boasts the world’s strongest supplements available.

TOPICS: Business, Medical, News: Pharma, Newsdesk, State: Illinois
 
» Continue Reading

Paragon BioTeck Inc to Distribute Horus Pharma Ilast Ocular Hygiene in U.S. with Exclusive Agreement

PORTLAND, Ore. /eNewsChannels/ — NEWS: Paragon BioTeck, Inc. signs a distribution agreement with Horus Pharma for rights to supply the Ilast range of its medical-grade ocular hygiene and lid care products within the United States. It begins on an exclusive basis this month.

TOPICS: Business, Medical, News: Pharma, Newsdesk, State: Oregon
 
» Continue Reading

Paragon BioTeck and Bausch + Lomb sign Exclusive License Agreement for Phenylephrine

MADISON, N.J. /eNewsChannels/ — NEWS Apr 19, 2013: Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

TOPICS: Business, News: Pharma, Newsdesk, State: New Jersey
 
» Continue Reading

RXCut Plus announces new website designed to help people get the best prescription drug prices

DOVER, Pa. /eNewsChannels/ — RXCut(R) Plus announced this week a new website that is designed to help people get the best prescription price available. ‘Our cutting-edge pharmacy price search is tightly integrated with Google Maps technology making it faster and easier for people to access pharmacy information,’ Gerard Ferro, founder and CEO RXCut(R) Plus, says.

TOPICS: Business, News: Pharma, Newsdesk, State: Pennsylvania
 
» Continue Reading

New products featured in Laboratory Supply Distributors’ latest catalog serve chromatography, biotechnology, pharma markets

MILLVILLE, N.J. /eNewsChannels/ — Laboratory Supply Distributors Corp., a provider of diverse products for the chromatography, biotechnology, pharmaceutical and environmental industries, today announced the launch of its 2013 catalog. It showcases many new products for the life science and biotech markets.

TOPICS: Business, News: Pharma, Newsdesk, State: New Jersey
 
» Continue Reading

Make 2013 a Year Without Head Lice!

BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give […]

TOPICS: National News, News: Pharma, State: Connecticut
 
» Continue Reading

Make 2013 a Year Without Head Lice!

BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give […]

TOPICS: National News, News: Pharma, State: Connecticut
 
» Continue Reading

Make 2013 a Year Without Head Lice!

BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give […]

TOPICS: National News, News: Pharma, State: Connecticut
 
» Continue Reading

Make 2013 a Year Without Head Lice!

BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give […]

TOPICS: National News, News: Pharma, State: Connecticut
 
» Continue Reading

Make 2013 a Year Without Head Lice!

BRIDGEPORT, Conn. (SEND2PRESS NEWSWIRE) — Head lice love the holidays as much as kids do, says George Coleman, founder of Dermedics Laboratories and master-mind behind the only non-toxic, FDA registered head lice treatment and repellent used by the U.S. Department of Health and Human Services to treat and prevent head lice infestations. Holiday parties give […]

TOPICS: National News, News: Pharma, State: Connecticut
 
» Continue Reading

Facts of Lice: Head Lice Spread Fast, So Prevention is Key, says George Coleman, founder and president of Connecticut’s Dermedics Laboratories

BRIDGEPORT, Conn. /eNewsChannels/ — October is the month the kids begin to scratch, says George Coleman, founder and president of Connecticut’s Dermedics Laboratories. That’s because the start of a new school year has children literally putting their heads together – and that’s how head lice infestations get started.

TOPICS: Business, News: Pharma, Newsdesk, State: Connecticut
 
» Continue Reading

Marketing Research Company CMI adds Paul Gondek Ph.D to Healthcare Solutions Practice

ATLANTA, Ga. /eNewsChannels/ — Paul Gondek has joined CMI to expand the company’s Healthcare Solutions practice to support healthcare, pharmaceutical, and medical device companies. As vice president client solutions and healthcare lead, Gondek will further enhance an experienced pharmaceutical team, using advanced analytics and immersive techniques to provide strategic insights that brand teams can use.

TOPICS: Business, News: Pharma, Newsdesk, State: Georgia
 
» Continue Reading

CMI’s Mike Mabey to Co-Present with Pfizer Specialty at 2012 PMRG Annual National Conference

ATLANTA, Ga. /eNewsChannels/ — CMI’s Mike Mabey, vice president, client solutions, and Jarod Ricci, senior manager, market analytics, Pfizer (NYSE:PFE), will present ‘Using Information-Seeking Behavior to Drive Segment-Specific Communication Strategies’ at the 2012 PMRG (Pharmaceutical Marketing Research Group) Annual National Conference.

TOPICS: Business, Events, News: Pharma, Newsdesk, State: Georgia
 
» Continue Reading

E’shee Clinical Esthetic announce Elixir of Life KI Therapy Serum

PHILADELPHIA, Pa. /eNewsChannels/ — E’shee Clinical Esthetic announced this week a new addition to its product line of skin serums – Elixir of Life KI Therapy Serum – designed to deliver ultimate skin rejuvenation.

TOPICS: Beauty Products, Business, News: Pharma, News: Product Launches, Newsdesk, State: Pennsylvania
 
» Continue Reading

Highland Ophthalmology Associates Offers ProKera to Corneal Patients

NEW WINDSOR, N.Y. /eNewsChannels/ — Mary Davidian, M.D., of Highland Ophthalmology Associates, a leading eye surgeon in The Hudson Valley, announces offering her patients a unique corneal wound repair and healing device called ProKera(R). Today, ProKera(R) is the only medical device that can provide wound healing to patients afflicted with a damaged cornea, the outer transparent surface of the eye.

TOPICS: Business, News: Pharma, Newsdesk
 
» Continue Reading

Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy

AUSTIN, Texas /eNewsChannels/ — Bio-Medical Services has received USDA approval and is now offering ACTT(TM) – allergy drop immunotherapy – as an alternative method for administering allergy treatment for pet allergy patients. An in-house pilot study is now underway, and preliminary findings are expected in the Fall of 2012.

TOPICS: Business, News: Pharma, Newsdesk, State: Texas
 
» Continue Reading

Reaction Biology today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain

MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.

TOPICS: Business, Medical, News: Pharma, Newsdesk, State: Pennsylvania
 
» Continue Reading

Soy Labs, LLC and the Missouri Plant Science Center to spur innovation and economic development in Missouri

MEXICO, Mo. /eNewsChannels/ — Missouri Gov. Jay Nixon, whose job-creation strategy has focused on investing in science, technology and innovation, and encouraging and incentivizing entrepreneurship, selected Soy Labs and the Missouri Plant Science Center on Friday, as the site to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act.

TOPICS: Agriculture, Business, Economic Development, News: Pharma, Newsdesk, State: Missouri, World: Mexico
 
» Continue Reading

E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream

PHILADELPHIA, Pa. /eNewsChannels/ — E’shee Clinical Esthetic introduces the next step in anti-aging skin care – White Truffle Radiance Cream – an amazingly powerful skin anti-oxidant. This supremely elegant formula combines the finest bioengineering technologies.

TOPICS: Beauty Products, Business, News: Pharma, News: Product Launches, Newsdesk, State: Pennsylvania
 
» Continue Reading

City of Scranton, Pa., selects Millennium Administrators, Inc. to Provide Benefit Administration for Active Fire and Police

SCHWENKSVILLE, Pa. /eNewsChannels/ — Millennium Administrators, Inc., a benefits administrator, has signed a contract with the City of Scranton to provide benefit administration services for over 500 city employees. Millennium is providing administrative oversight for the city benefit program, including cost containment initiatives, claim audits and administrative services

TOPICS: Business, Government, Insurance, News: Pharma, Newsdesk, State: Pennsylvania
 
» Continue Reading

ProtiLife Distribution Inc. Launches Health-Focused Online Weight Loss Program for American Women

MONTREAL, Quebec /eNewsChannels/ — ProtiLife Distribution Inc., a leader in the development and distribution of high-quality protein supplements for over 20 years, has launched its online weight loss program to the U.S. market.

TOPICS: Business, News: Pharma, Newsdesk
 
» Continue Reading

Multi-Tier Micro Plate System announced by Laboratory Supply Distributors Corp.

VINELAND, N.J. /eNewsChannels/ — Designed for analytical research and clinical diagnostic testing, Laboratory Supply Distributors Corp. announces the 96-Well Multi-Tier™ Micro Plate System. Its unique, patented design allows for more flexibility and ease of use.

TOPICS: Business, News: Pharma, Newsdesk, State: New Jersey
 
» Continue Reading

REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA

SAN MARINO, Calif. /eNewsChannels/ — Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.

TOPICS: Business, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

New Strategies and Business & Decision Partner to Bring Industry Leading ERP Solutions to Pharma Industry

PHOENIX, Ariz. /eNewsChannels/ — As a part of Business & Decision’s ongoing focus in the Life Science market, we are delighted to announce a partnership with New Strategies, the creators of ‘AX for Pharma’ an industry leading Enterprise Resource Planning solution for the Pharmaceutical industry. This solution, which is based on Microsoft Dynamics AX, has been designed to address the primary business process needs of a Life Science / Pharmaceutical organization.

TOPICS: Business, Computing, News: Pharma, Newsdesk, State: Arizona
 
» Continue Reading

Hormone Therapy and Breast Cancer: Is There a Connection? ask Practitioners from Belvidere Pharmacy and Balancing Health

SOMERSET, N.J. /eNewsChannels/ — From the blogosphere to mainstream media, there’s been a recent-and disturbing-buzz on a connection between hormone replacement therapy and a higher risk for advanced-stage breast cancer in post-menopausal women. The recent media focus stems from a study published in the Oct. 2010 issue of the Journal of the American Medical Association. Practitioners from Belvidere Pharmacy and Balancing Health, both experts in women’s health, examine the issue.

TOPICS: Business, News: Pharma, Newsdesk, State: New Jersey
 
» Continue Reading

Ethnographer Laura Winn Johnson to Present at PMRG Institute

ATLANTA, Ga. /eNewsChannels/ — CMI, a full-service marketing research company, has been chosen for the second consecutive year to present a session at The Fourth Annual Meeting of the PMRG Institute in Boston, Mass., on Oct. 24-26, 2010. The theme for this year’s conference is ‘Navigating Healthcare’s Shifting Currents: Essential Techniques for the Healthcare Marketing Researcher.’

TOPICS: Business, News: Pharma, Newsdesk, State: Georgia
 
» Continue Reading

Reaction Bio Receives National Cancer Institute Grant for Epigenetic Platform

MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.

TOPICS: Business, News: Pharma, Newsdesk, State: Pennsylvania
 
» Continue Reading

Epeius Bio’s Rexin-G® Receives High-tech Validation as Strategic Anti-cancer Agent

SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime […]

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

BIO Investor Forum: Epeius Biotechnologies Investment Opportunity

SAN FRANCISCO, Calif. — Epeius Biotechnologies Corporation (www.epeiusbiotech.com), an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San […]

TOPICS: Biotech and Biometric, California, Events, Investment Services, News: Pharma, Newsdesk
 
» Continue Reading

Epeius Biotech Reports Dose-Dependent Efficacy and Survival Benefits, Efficacy of Rexin-G in Metastatic Pancreas Cancer

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, which […]

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G® has once again accomplished what standard cancer treatments and […]

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Whistleblower Mark Whitacre says ‘The Informant’ Movie is Only Part of the Story

NEW YORK CITY, N.Y. — As Mark Whitacre, COO of Cypress Systems, Inc., walked the red carpet on September 15 during the premiere of “The Informant,” he had something to say: he is NOT the same man who blew the whistle on his employer in the early 1990’s, putting him in the spotlight of one […]

TOPICS: Entertainment, Films and Film Making, News: Pharma, Newsdesk, State: New York
 
» Continue Reading

Pharmaceutical eMarketing using Social Media: How to Use It Effectively

NEW YORK, N.Y. — Eularis is announcing the release of its report “How To Harness The Power Of Social Media In Pharmaceutical eMarketing.” This report puts to rest the issues around “can’t,” and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives. “I see this common belief that […]

TOPICS: Advertising, Business, News: Pharma, News: Reports and Studies, Newsdesk, State: New York
 
» Continue Reading

Patented Green Technology is Potential Silver Bullet for Swine Flu and Most Common Infections

FORT LAUDERDALE, Fla. — Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in the U.S. […]

TOPICS: Business, News: Pharma, Newsdesk, State: Florida
 
» Continue Reading

Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results […]

TOPICS: Biotech and Biometric, California, News: Pharma, Newsdesk
 
» Continue Reading

Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate […]

TOPICS: Business, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

The World’s Smallest Hero! Epeius Bio’s Rexin-G, Targeted Therapy for Metastatic Cancers

SAN MARINO, Calif. — Epeius Biotechnologies’ Rexin-G® is the world’s smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high […]

TOPICS: California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Eularis Releases Comprehensive Report on Effective Pharmaceutical eMarketing

NEW YORK, N.Y. — Eularis is announcing the release of an update to its report “Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web 2.0 and Beyond.” The comprehensive report has been created to demystify the world of eMarketing and Social Media to provide Pharmaceutical marketers with a competitive edge and the latest information on […]

TOPICS: Advertising, News: Pharma, Newsdesk, State: New York
 
» Continue Reading

Eularis to Hold Pharma Marketing ROI MasterClass in London

LONDON, U.K. — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing budgets often represent a major portion of a company’s cost […]

TOPICS: Advertising, Events, News: Pharma, Newsdesk, World: U.K.
 
» Continue Reading

Epeius’ Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma

SAN MARINO, Calif. — Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is […]

TOPICS: Business, California, Medical, News: Pharma, Newsdesk, State: New York
 
» Continue Reading

Hot Rising Fitness Star Natalie Waples Takes On Steroids Issue in Fitness Biz

ORLANDO, Fla. — Natalie Waples is one of the brightest young stars in the fitness firmament. The eye-catching Canadian made her pro debut last season, winning her first professional event at the IFBB North American Figure Championships. She has graced the September ’08 cover of Inside Fitness Magazine and her new DVD, “Building a Beautiful […]

TOPICS: Featured Story 1, Fitness, News: Pharma, Newsdesk, State: Florida
 
» Continue Reading

Cancer-Destroying Biotech: Epeius Bio Launches Rexin-G eBook Tutorial

SAN MARINO, Calif. — Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated […]

TOPICS: Biotech and Biometric, California, News: Pharma, News: Publishing, Newsdesk
 
» Continue Reading

Epeius Bio’s Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemo-Resistant Pancreatic Cancer

SAN MARINO, Calif. — Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, […]

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Silver Safety Committee Gives Guidelines for Safe Use of Any Ionic or Colloidal Silver Supplement

FORT LAUDERDALE, Fla. — The Silver Safety Committee this week announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver. The Silver Safety Committee consists of doctors, chemistry professors and […]

TOPICS: Featured Story 1, Fitness, News: Pharma, News: Websites, Newsdesk, State: Florida
 
» Continue Reading

Epeius Bio Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine

SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well […]

TOPICS: Biotech and Biometric, Business, California, News: Patent and Trademark, News: Pharma, Newsdesk
 
» Continue Reading

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Cancers

SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G […]

TOPICS: California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Eularis Analyzes Pre-Launch Brand Planning with New Pharma Industry Report

LONDON, U.K. — In today’s environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits – until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. […]

TOPICS: Advertising, Business, News: Pharma, Newsdesk, World: U.K.
 
» Continue Reading

Rexin-G Clinical Trials for Pancreatic Cancer and Breast Cancer Open in New York

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. […]

TOPICS: California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)

FRESNO, Calif. — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at cypsystems.com […]

TOPICS: California, News: Pharma, Newsdesk
 
» Continue Reading

Epeius Biotechnologies Reveals a New Generation of Tools for Medical Gene Delivery

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled “Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ,” was published in the October issue of […]

TOPICS: California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Eularis Releases First-Ever Pharma Study: ROI of Pre-Launch Named Patient Programs

NEW YORK, N.Y. and LONDON, U.K. — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, “Implementing a pre-launch named patient programme – evidence of increased market share,” provides pharmaceutical companies with insight and mathematical justification into the cash […]

TOPICS: Advertising, News: Pharma, News: Reports and Studies, Newsdesk, State: New York
 
» Continue Reading

Epeius Biotechnologies Rexin-G® for Metastatic Cancer Highlighted by National Cancer Institute Journal

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine […]

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Eularis Analyzes Most Effective Generics Defense Strategies with New Pharma Industry Report

NEW YORK, N.Y. and TOKYO, JAPAN — Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company profits. In the United States, the Generics Industry claims more […]

TOPICS: Advertising, Business, Featured Story 1, News: Pharma, News: Reports and Studies, Newsdesk, State: New York
 
» Continue Reading

Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit […]

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Eularis Challenges Pharma Industry in 2008: Are You Measuring the Wrong Things

LONDON UK, and TOKYO Japan — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years. […]

TOPICS: Advertising, News: Pharma, Newsdesk, World: U.K.
 
» Continue Reading

Intravenous Infusions of Epeius Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity

SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007). In this […]

TOPICS: California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies

RICHMOND, Texas — CYNACON / OCuSOFT (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to announce that as a convenience to all patients, OCuSOFT(R) Lid Scrub(TM) Plus is now available in CVS pharmacies, nationwide. OCuSOFT(R), Inc., recognized as the market leader, recently introduced OCuSOFT(R) Lid Scrub(TM) […]

TOPICS: News: Pharma, Newsdesk, Retail, State: Texas
 
» Continue Reading

Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes

SAN MARINO, Calif. — ASCO 2008 — Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G followed by Reximmune-C-for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J Clin Oncol 26:3077, 2008). Rexin-G and Reximmune-C are pathotropic (disease-seeking) […]

TOPICS: Business, California, Medical, News: Pharma, Newsdesk, State: Texas
 
» Continue Reading

TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity

SAN MARINO, Calif. — Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, […]

TOPICS: California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer

SAN MARINO, Calif. — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the […]

TOPICS: California, Featured Story 1, News: Pharma, Newsdesk
 
» Continue Reading

Eularis to Address Marketing Return at Japanese Pharma Marketing Excellence Conference

TOKYO and LONDON, UK — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan. At 11:45 a.m. on Monday, 19 May 2008, Dr. […]

TOPICS: Advertising, News: Pharma, Newsdesk, World: Japan
 
» Continue Reading

Dr. Andree Bates to Address Pharma Research ROI

NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation titled, “How to Tell if You Are Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return.”

TOPICS: Advertising, Featured Story 1, News: Pharma, Newsdesk, State: New York, Story Index, World: U.K.
 
» Continue Reading

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G’s anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G.

TOPICS: California, Medical, News: Pharma, Newsdesk, Story Index
 
» Continue Reading

Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Advocating Special Type of Selenium

FRESNO, Calif. — Chairman and CEO, Paul Willis stated, “Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company’s chief operating officer and president of operations.” Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans-and people around the world-to consume a special type of selenium known as SelenoExcell(R).

TOPICS: California, Healthcare, News: Pharma, Newsdesk, Story Index
 
» Continue Reading

Patent for Targeted Injectable Gene Delivery In Vivo Awarded to Epeius Biotech

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent, Rexin-G.

TOPICS: Biotech and Biometric, California, News: Pharma, Newsdesk, Story Index
 
» Continue Reading

Patient Adherence Exposed in Pharma Industry Report

NEW YORK, N.Y. and LONDON, U.K. — Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, “Ensuring Profitable Patient Adherence Programs.”

TOPICS: News: Pharma, News: Reports and Studies, Newsdesk, State: New York, Story Index, World: U.K.
 
» Continue Reading

Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference London

NEW YORK, N.Y. and LONDON, England — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry. On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled, “Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the Pharma Industry?”

TOPICS: Advertising, News: Pharma, Newsdesk, State: New York, Story Index, World: U.K.
 
» Continue Reading

Tom Brady, STG Media Tackle Myo-Med Campaign

TEMPE, Ariz. — Superbowl quarterback, Tom Brady has agreed to be the face of Myo-Med, for the launch of their 2008 media campaign. BioForce, the makers of Myo-Med, recently appointed STG Media Corp. as their agency of record to assist them in creating brand awareness among athletes and arthritis sufferers nationwide.

TOPICS: Advertising, Celebrity, News: Pharma, Newsdesk, State: Arizona, Story Index
 
» Continue Reading

deverus, Inc. Partners with eScreen Inc. to Offer Instant Drug Testing Device

AUSTIN, Texas — deverus, Inc., the leader in background screening technology, recently announced a partnership with eScreen Inc., a company known for its innovative drug screening technology. After comparing different providers, deverus found that no one could match the selection and quality of products that eScreen had to offer. Through eScreen, deverus will now provide clients with technology that creates a web-based system that delivers faster drug test results and paperless transactions.

TOPICS: Alliances, Internet, News: Pharma, Newsdesk, State: Texas, Story Index
 
» Continue Reading

Epeius Bio Applauds the Belated Scholarship of Their Academic Contemporaries, as Targeted Gene Therapy Comes of Age in 2007

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled “In Vivo Barriers to Gene Delivery” was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.

TOPICS: Biotech and Biometric, California, News: Pharma, Newsdesk, Story Index
 
» Continue Reading

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G

SAN MARINO, Calif. — Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.

TOPICS: Biotech and Biometric, California, Medical, News: Pharma, Newsdesk, Story Index
 
» Continue Reading